TB-500 Research Studies: Identity Before Results

Research use only. This page reads named research records and their material-identity limits. It does not provide a medical, veterinary, dosing, administration, safety, or outcome recommendation.

A TB-500 result starts with an identity question

Searching for TB-500 research studies returns papers that may use a market name, an acetylated seven-residue fragment, or the separate protein name thymosin beta-4. Those labels cannot be collapsed before the test article in the cited record has been checked. A reported result belongs first to the named material, model, comparator, and endpoint in that record.

This page uses three identity filters. First, the paper must state the material name used in its experiment. Second, a sequence or fragment name must stay attached to the source that actually reports it. Third, a full-length thymosin beta-4 record remains a full-length record unless its own text identifies the same test article as TB-500. These filters do not establish the composition, purity, or equivalence of a separately supplied material.

Record 1: an authors’ TB-500 label in a four-arm rat experiment

Bicer et al. described one study material as “synthetic thymosin beta-4 (TB-500)” in a standardized Achilles-tendon transection-and-repair experiment. The paper enrolled 32 male 12-week-old Sprague-Dawley rats, allocating eight animals each to control, BPC-157, TB-500, and combined BPC-157 plus TB-500 groups. The TB-500 group was reported as 60 microg/kg/day, administered intraperitoneally for four postoperative weeks; tendons were then collected for biomechanical or histological evaluation. ^[1]

Within that study, the comparator was the control group in the same surgical model and collection schedule. The abstract reported a statistically significant higher maximum-load-to-failure value in the TB-500 group versus control (p < 0.05), lower total Bonar score (p = 0.016), and lower total Movin score (p = 0.017). It also reported no additional benefit of the combined group over either individual agent. These are four-week observations in the named rat groups, not a finding about a catalogue lot, another sequence, another tissue, or another species. ^[1]

The source passes the first filter because it explicitly joins its study label “synthetic thymosin beta-4” and “TB-500.” It does not, from the directly accessible abstract alone, provide a sequence, analytical purity result, manufacturer, or lot identifier. The record therefore does not justify relabelling its result as a result of Ac-LKKTETQ, a verified full-length protein, or an unrelated material called TB-500.

Record 2: a sequence-defined TB-500 metabolism and cell-assay study

Rahaman et al. defined TB-500 as Ac-LKKTETQ, an acetylated fragment derived from the active site of thymosin beta-4. Their primary study developed and validated a UHPLC-Q-Exactive Orbitrap MS method for TB-500 and metabolites, examined metabolism in human serum, in-vitro enzyme systems, and urine from rats treated with TB-500, and evaluated cytotoxicity and a wound-healing assay in fibroblasts. ^[2]

For this record, the exact fragment name is the identity anchor. The abstract reported Ac-LK as the highest-concentration primary metabolite in rat samples collected over 0-6 hours, Ac-LKK detected up to 72 hours, no cytotoxicity of the parent or metabolites in the stated assay, and a significant wound-healing-assay result only for Ac-LKKTE versus its control. The authors suggested that previously reported wound-healing activity attributed to TB-500 might instead relate to Ac-LKKTE. These are analytical and cell-assay observations under the reported systems; they do not establish a clinical, veterinary, or product outcome. ^[2]

The PubMed abstract identifies rat urine, human serum, in-vitro enzyme systems, and fibroblast assays, but it does not report the rat administration amount, route, frequency, experimental-unit count, or assay concentrations. Those fields should be logged as unreported from this directly accessible record rather than filled from another TB-500 or thymosin beta-4 paper.

Record 3: fragment identification is not an efficacy study

Esposito et al. detected and identified the N-terminally acetylated thymosin beta-4 17-23 fragment, Ac-LKKTETQ, in a formulation described as TB-500, using high-performance liquid chromatography and high-resolution mass spectrometry. The authors also synthesized Ac-LKKTETQ and proposed an analytical detection strategy for plasma and urine. ^[3]

This source passes a fragment-identity filter, but its endpoint is analytical detection and identification. It does not report an animal or human intervention, comparison group, dose, route, duration, or biological outcome. It can support the Ac-LKKTETQ identity statement for the reported formulation; it cannot supply an effect claim for that fragment or for a full-length thymosin beta-4 preparation.

Where a full-length thymosin beta-4 citation stops

UniProt’s reviewed human TMSB4X entry lists thymosin beta-4 as a 43-amino-acid protein. ^[4] Carlier et al. studied thymosin beta-4 in a biochemical actin-assembly system, reporting observations across concentrations up to 300 micromolar. The paper calls its material thymosin beta-4 and describes G-actin and F-actin interactions; it does not identify TB-500 or Ac-LKKTETQ as its test article. ^[5] It therefore fails the TB-500 identity filter. The study remains useful as a defined full-length thymosin beta-4 source, but its in-vitro observations should not be relabelled as TB-500 research results.

How to verify a claimed TB-500 study

Read the original title, methods, abstract, figures, and reference list in that order. Preserve the authors’ material wording before importing a result into a literature note. Then keep the test system beside the material: a surgically repaired rat tendon, rat urine after treatment, human serum, an enzyme system, a fibroblast assay, and a purified actin system are separate settings. If the record does not provide a sequence, dose, route, comparator, or analytical identity, mark that field as unavailable from the cited source.

For terminology and analytical provenance, see TB-500 Analytical Identity: Ac-LKKTETQ, Fragment Names, and MS Records. For the broader name-and-document boundary, see TB-500 and Thymosin Beta-4: Nomenclature, Source Scope and Documentation Review. These related pages do not turn one source’s test article into another source’s material.

Sources

1. Bicer O, Adanir O, Guleryuz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. 2026;37:822-837. PMID 42542926. PubMed record.
2. Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive Orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B. 2024;1235:124033. PMID 38382158. PubMed record.
3. Esposito S, Deventer K, Geldof L, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012;4:733-738. PMID 22962027. PubMed record.
4. UniProt Consortium. Thymosin beta-4, human, TMSB4X, reviewed entry P62328. UniProt record.
5. Carlier MF, Didry D, Erk I, et al. Tbeta 4 is not a simple G-actin sequestering protein and interacts with F-actin at high concentration. Journal of Biological Chemistry. 1996;271:9231-9239. PMID 8621582. PubMed record.

This summary reports study details from the cited source and does not provide medical, veterinary, dosing, administration, safety, or treatment guidance. It does not represent a product-use recommendation.

Product-record boundary: The related TB-500 research material page is a catalogue record. Its label, lot documents, and analytical files must be reviewed separately; they do not prove equivalence with the rat, metabolite, plasma, fibroblast, or actin-system materials in the cited studies. This page targets the exact keyword tb-500 research studies by resolving identity before comparing results.